[go: up one dir, main page]

UY27615A1 - ACIDS 3 - (IMIDAZOLIL) - 2 ALCOXIPROPANOICS - Google Patents

ACIDS 3 - (IMIDAZOLIL) - 2 ALCOXIPROPANOICS

Info

Publication number
UY27615A1
UY27615A1 UY27615A UY27615A UY27615A1 UY 27615 A1 UY27615 A1 UY 27615A1 UY 27615 A UY27615 A UY 27615A UY 27615 A UY27615 A UY 27615A UY 27615 A1 UY27615 A1 UY 27615A1
Authority
UY
Uruguay
Prior art keywords
alcoxipropanoics
imidazolil
acids
alkyl
hydrogen
Prior art date
Application number
UY27615A
Other languages
Spanish (es)
Inventor
Mark E Bunnage
Robert J Maguire
Kohn Steele
Daavid J Bulll
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY27615A1 publication Critical patent/UY27615A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de acuerdo con la fórmula ( I ) en la que n el 0-3, R1 es alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 o alquinilo C2-6, heterociclo aromático, arilo o hidrógeno y cada uno de R2, R3, R4, R5, R6, R7,R8, y R9, selecciona independientemente entre 10 hidrógeno y alquilo C1-6 opcionalmente sustituido, o R5, y R8, son una cadena alquileno, son novedosos. Estos compuestos son útiles en el tratamiento de afecciones trombóticas y otras patalogías asociadas con la deposición de fibrina.The compounds according to formula (I) in which n 0-3, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, aromatic heterocycle, aryl or hydrogen and each of R 2, R3, R4, R5, R6, R7, R8, and R9, independently selects between hydrogen and optionally substituted C1-6 alkyl, or R5, and R8, are an alkylene chain, are novel. These compounds are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.

UY27615A 2002-01-22 2003-01-20 ACIDS 3 - (IMIDAZOLIL) - 2 ALCOXIPROPANOICS UY27615A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
UY27615A1 true UY27615A1 (en) 2003-08-29

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27615A UY27615A1 (en) 2002-01-22 2003-01-20 ACIDS 3 - (IMIDAZOLIL) - 2 ALCOXIPROPANOICS

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
JP2012511008A (en) * 2008-12-05 2012-05-17 持田製薬株式会社 Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8946443B2 (en) 2010-03-18 2015-02-03 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
KR101704095B1 (en) * 2010-03-18 2017-02-09 다이이찌 산쿄 가부시키가이샤 Cycloalkyl-substituted imidazole derivative
CN105263928A (en) 2013-06-10 2016-01-20 赛诺菲 Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as medicines
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
NZ763299A (en) 2017-09-14 2025-09-26 Daiichi Sankyo Co Ltd Compound having cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
MXPA03001425A (en) * 2000-08-17 2003-06-06 Pfizer PHARMACEUTICAL COMPOUNDS.

Also Published As

Publication number Publication date
WO2003061652A8 (en) 2004-09-10
TW200302094A (en) 2003-08-01
ECSP045200A (en) 2004-08-27
EA200400716A1 (en) 2004-12-30
WO2003061652A1 (en) 2003-07-31
IS7310A (en) 2004-06-14
OA12756A (en) 2006-07-03
CA2472238A1 (en) 2003-07-31
MXPA04006573A (en) 2004-10-04
PE20030929A1 (en) 2003-11-05
MA27167A1 (en) 2005-01-03
JP2005520811A (en) 2005-07-14
HRP20040659A2 (en) 2004-10-31
BR0307016A (en) 2004-11-03
EP1467731A1 (en) 2004-10-20
IL162677A0 (en) 2005-11-20
KR20040077775A (en) 2004-09-06
TNSN04121A1 (en) 2006-06-01
PA8563501A1 (en) 2004-08-31
PL371487A1 (en) 2005-06-13
CN1620291A (en) 2005-05-25
NO20043457L (en) 2004-08-19
AR038197A1 (en) 2005-01-05
AP2004003084A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
UY27522A1 (en) PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
NO20005237D0 (en) Heterocyclic substituted amides used as calpain inhibitors
ATE396993T1 (en) TETRAHYDROPYRANYL-CYCLOPENTYL-TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
CY1107903T1 (en) ACYLAMINOTHIACEALE PRODUCTS AND THEIR USE AS BETA-AMYLOID INHIBITORS
CO5611139A2 (en) PIRIMIDINAS ARIL REPLACED AND THE USE OF THE SAME
PE20060570A1 (en) QUINAZOLINE AND ISOQUINOLINE PIPERIDYL COMPOUNDS SUBSTITUTED AS PHOSPHODIESTERASE PDE-10 INHIBITORS
ES2184280T3 (en) INDOL COMPOUNDS AS COX-2 'INHIBITORS.
ATE404538T1 (en) TETRAHYDROPYRANYLCYCLOPENTYLTETRAHYDROISOCHINO-LINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
ES2186874T3 (en) ANALOGS OF M-AMIDINOPHENYL AS INHIBITORS OF FACTOR XA.
ES2173846T3 (en) INDOL BICICLOCARBONIL COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS AND AS COX-2 INHIBITORS.
UY27615A1 (en) ACIDS 3 - (IMIDAZOLIL) - 2 ALCOXIPROPANOICS
AR042362A1 (en) DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20040528A1 (en) PEPTIDE-DEFORMYLASE INHIBITORS
MXPA04005940A (en) 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases.
PE20030611A1 (en) LINEAR BASIC COMPOUNDS THAT HAVE ANTAGONIST ACTIVITY OF NK-2 AND ITS FORMULATIONS
EA200500133A1 (en) PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF OXYTOCIN
PE20050120A1 (en) KITCHENS WITH A MODIFIED LACTONE RING
DOP2003000564A (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS
PE20060103A1 (en) NEW 5-ACYLINDOLINONES WITH CYCLOALKYL CONTENT AND ITS PREPARATION AS A MEDICINAL PRODUCT
CO5540311A2 (en) USEFUL PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS
PE20010165A1 (en) DERIVATIVES OF 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETILCROMANO AS ANTAGONISTS OF SUBSTANCE P
UY27616A1 (en) ACIDS 3 - (AMIDAZOLIL) - AMINOPROPANOICS
DOP2003000560A (en) ACIDS 3- (IMIDAZOLIL) -2-AMINOPROPANOICS
AR054414A1 (en) ESPIRO-HYDANTOINE COMPOUNDS REPLACED WITH PIRIDILE. PHARMACEUTICAL COMPOSITIONS.
AR023528A1 (en) DERIVATIVES OF CICLOBUTEN-3,4-DIONA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126